Scientists have been laboring to detect cancer and a host of other diseases in people using promising new biomarkers called “exosomes.” Indeed, Popular Science magazine named exosome-based cancer diagnostics one of the 20 breakthroughs that will shape the world this year. Exosomes could lead to less invasive, earlier detection of cancer, and sharply boost patients’ odds of survival.
Green tea has long been known for its anti-oxidant, anti-cancer, anti-aging and anti-microbial properties. A group of researchers from the Institute of Bioengineering and Nanotechnology in Singapore has taken the health benefits of green tea to the next level by using one of its ingredients, the antioxidant epigallocatechin gallate, to develop a drug delivery system that kills cancer cells more efficiently.
Mutations in the gene that encodes BRCA2 are well known for raising the risk of breast cancer and other cancers. Although the protein was known to be involved in DNA repair, its shape and mechanism have been unclear, making it impossible to target with therapies. Researchers in the U.K. purified the protein and used electron microscopy to reveal its structure and how it interacts with other proteins and DNA.
Only a minority of suspicious mammograms actually leads to a cancer diagnosis, which results in lots of needless worry and spent time for women and their families. Ultrasound elastography could be an excellent screening tool but it requires a lot of skill and interpretation. In an effort to improve results, researchers in Michigan have developed a virtual “breast”, allowing medical professionals to practice in the laboratory.
The discovery of a gene mutation that causes a rare premature aging disease could lead to the development of drugs that block the rapid, unstoppable cell division that makes cancer so deadly. Scientists at the Univ. of Michigan recently discovered a protein mutation that causes the devastating disease dyskeratosis congenita, in which precious hematopoietic stem cells can't regenerate and make new blood.
Researchers at the Univ. of Michigan have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods. They used the platform to identify a novel antibody that is undergoing further investigation as a potential treatment for breast, ovarian and other cancers.
Years before they show any other signs of disease, pancreatic cancer patients have very high levels of certain amino acids in their bloodstream, according to a new study. This finding, which suggests that muscle tissue is broken down in the disease’s earliest stages, could offer new insights into developing early diagnostics for pancreatic cancer, which kills about 40,000 Americans every year.
Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of Massachusetts Institute of Technology (MIT) researchers has now hijacked that delivery system for a different purpose: administering cancer drugs.
A new, ultrasensitive biosensor made from graphene has been used to detect molecules that indicate an increased risk of developing cancer. The biosensor has been shown to be more than five times more sensitive than bioassay tests currently in use, and was able to provide results in a matter of minutes, opening up the possibility of a rapid, point-of-care diagnostic tool for patients.
A new $1.9 million study at the Univ. of Michigan seeks to make low-dose computed tomography scans a viable screening technique by speeding up the image reconstruction from half an hour or more to just five minutes. The advance could be particularly important for fighting lung cancers, as symptoms often appear too late for effective treatment.
For detecting cancer, manual breast exams seem low-tech compared to other methods such as MRI. But scientists are now developing an “electronic skin” that “feels” and images small lumps that fingers can miss. Knowing the size and shape of a lump could allow for earlier identification of breast cancer, which could save lives.
Key discoveries about breast cancer, Parkinson's disease and the body's handling of defective proteins have earned prestigious medical awards for five scientists. The Albert and Mary Lasker Foundation announced the winners Monday. Each prize includes a $250,000 honorarium. The awards will be presented Sept. 19 in New York.
New research in Europe suggests that testing the temperature of breath could be a simple and noninvasive method to either confirm or reject the presence of lung cancer. Many research teams have been looking at the possibility of using breath tests for a number of cancers but this is the first study looking at breath temperature as a marker in lung cancer.
U.S. regulators have approved the first drug in a new class of cancer medicines that work by stimulating the immune system, a Merck drug developed for treating deadly skin cancer. The Food and Drug Administration says it has granted accelerated approval to Merck's Keytruda, for treating melanoma that's spread or can't be surgically removed, in patients previously treated with another drug.
Removing both breasts to treat cancer affecting only one side doesn't boost survival chances for most women, compared with surgery that removes just the tumor, a large study suggests. The results raise concerns about riskier, potentially unnecessary operations that increasing numbers of women are choosing.
Researchers have devised a new way to separate cells by exposing them to sound waves as they flow through a tiny channel. Their device, about the size of a dime, could be used to detect the extremely rare tumor cells that circulate in cancer patients’ blood, helping doctors predict whether a tumor is going to spread.
A multidisciplinary team of scientists from the Univ. of California, Los Angeles and Stanford Univ. has used a naturally occurring nanoparticle called a vault to create a novel drug delivery system that could lead to advances in the treatment of cancer and HIV. Their findings could lead to cancer treatments that are more effective with smaller doses and to therapies that could potentially eradicate the HIV virus.
Two Northwestern Univ. scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumor effects. As EphA3 is present in normal organs only during embryonic development but is expressed in blood cancers and in solid tumors, this antibody-based approach may be a suitable candidate treatment for solid tumors.
Scientists at Yale Univ. have developed a novel cancer immunotherapy that rapidly grows and enhances a patient’s immune cells outside the body using carbon nanotube-polymer composites; the immune cells can then be injected back into a patient’s blood to boost the immune response or fight cancer.
By combining magnetic nanoparticles with one of the most common and effective chemotherapy drugs, Argonne National Laboratory researchers have created a way to deliver anti-cancer drugs directly into the nucleus of cancer cells. They have created nano-sized bubbles, or “micelles,” that contain magnetic nanoparticles of iron oxide and cisplatin, a conventional chemotherapy drug also known as “the penicillin of cancer.”
A smart technology which involves smuggling gold nanoparticles into brain cancer cells has proven highly effective in lab-based tests in the U.K. The technique could eventually be used to treat glioblastoma multiforme, which is the most common and aggressive brain tumor in adults, and notoriously difficult to treat.
Scientists have known for decades that cancer can be caused by genetic mutations, but more recently they have discovered that chemical modifications of a gene can also contribute to cancer. These alterations, known as epigenetic modifications, control whether a gene is turned on or off. Analyzing these modifications can provide important clues to the type of tumor a patient has, and how it will respond to different drugs.
Researchers from the University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells. These synthetic ion transporters confirm a two-decades-old hypothesis that could point the way to new anticancer drugs while also benefitting patients with cystic fibrosis.
The Food and Drug Administration has approved the first screening test for colon cancer that uses patient DNA to help spot potentially deadly tumors and growths. The Cologuard test from Exact Sciences detects irregular mutations in a patient's stool sample that can be an early warning sign of cancer. Patients who test positive for the mutations should undergo a colonoscopy to confirm the results.